15353-j-veluchamy

160 | Chapter 6 42. Carlsten M, Childs RW. Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications. Frontiers in Immunology (2015) 6 :266. doi: 10.3389/fimmu.2015.00266. PubMed PMID: PMC4462109. 43. Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood (2013) 122 (8):1341-9. doi: 10.1182/blood-2013-03-478255. 44. Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nature immunology (2016) 17 (7):816-24. doi: 10.1038/ni.3470 http://www.nature.com/ni/journal/v17/n7/abs/ni.3470.html#supplementary -information. 45. Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Frontiers in immunology (2015) 6 :368. doi: 10.3389/ fimmu.2015.00368. PubMed PMID: PMC4515552. 46. Mellor J, Brown M, Irving H, Zalcberg J, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. Journal of Hematology & Oncology (2013) 6 (1):1. PubMed PMID: doi:10.1186/1756-8722-6-1. 47. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology (2014) 32 (11):1157-63. doi: doi:10.1200/JCO.2013.52.0924. PubMed PMID: 24616310. 48. Goede V, Klein C, Stilgenbauer S. Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin’s Lymphomas: A Glycoengineered Type II CD20 Antibody. Oncology Research and Treatment (2015) 38 (4):185-92. 49. Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, et al. Ocaratuzumab, an Fc- engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs (2014) 6 (3):749-55. Epub 2014/03/07. doi: 10.4161/ mabs.28282. PubMed PMID: 24594909; PubMed Central PMCID: PMCPMC4011919. 50. Oppenheim DE, Spreafico R, Etuk A, Malone D, Amofah E, Peña-Murillo C, et al. Glyco- engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. British Journal of Cancer (2014) 110 (5):1221-7. doi: 10.1038/bjc.2014.35. PubMed PMID: PMC3950873. 51. Delord J-P, Tabernero J, García-Carbonero R, Cervantes A, Gomez-Roca C, Bergé Y, et al. Open- label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS- mutant advanced colorectal carcinoma. European Journal of Cancer (2014) 50 (3):496-505. doi: http://dx.doi.org/10.1016/j.ejca.2013.10.015. 52. Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inoges S, et al. Antibody-dependent cell cytotoxicity (ADCC): Immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol (2017). Epub 2017/02/01. doi: 10.1038/icb.2017.6. PubMed PMID: 28138156. 53. Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discovery Today (2015) 20 (7):838-47. doi: http://dx.doi.org/10.1016/j.drudis.2015.02.008. 54. Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. Journal of Hematology &